Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control

References

• TraubeLUeber den zusammenhang von herz und nierenkrankeiten. Page IH. Effect on renal efficiency of lowering blood pressure in cases of essential hypertension and nephritisJ Clin Invest19341390916694258
   PubMedGoogle Scholar
• KlagMJWheltonPKRandallBLBlood pressure and end-stage renal disease in menN Engl J Med1996334113187494564
   PubMed Web of Science ®Google Scholar
• TextorSCRenal Parenchymal disease and hypertension atlas of diseases of the kidneySchrierRWISN Commission on Nephrology Informatics and NKF cyberNephrology20013 Chapter 2.4, (Figure 2.7).
   Google Scholar
• SmithMCDunnMJHypertension in renal parenchymal diseaseLaraghJHBrennerBMHypertension: Pathophysiology, Diagnosis and ManagementNew YorkRaven Press199520812102
   Google Scholar
• VanhouttePMBoulangerCMEndothelium-dependent responses in hypertensionHypertens Res19951887987584924
   PubMedGoogle Scholar
• LüscherTFBockHAThe endothelial L-arginine/nitric oxide pathway and the renal circulationKlin Wochenschr1991696036091753683
   PubMedGoogle Scholar
• LlinasMTGonzalezJDRodriguezFNavaETaddeiSSalazarFJRenal changes induced by nitric oxide and prostaglandin synthesis reduction: effects of trandolapril and verapamilHypertension19983126576649461237
   PubMed Web of Science ®Google Scholar
• ZouAPWuFCowleyAWJrProtective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulationHypertension199831Pt 22712769453315
   PubMed Web of Science ®Google Scholar
• StecDEMattsonDLRomanRJInhibition of renal outer medullary 20-HETE production produces hypertension in Lewis ratsHypertension199729Pt 23153199039121
   PubMed Web of Science ®Google Scholar
• CampeseVMNeurogenic factors and hypertension in renal diseaseKidney Int200057Suppl 75S2S6
   Google Scholar
• AsahiKIchimoriKNakazawaHNitric oxide inhibits the formation of advanced glycation end productsKidney Int2000581780178711012913
   PubMed Web of Science ®Google Scholar
• KlahrSMorrisseyJJThe role of vasoactive compounds, growth factors and cytokines in the progression of renal diseaseKidney Int200057Suppl 75S7S14
   Google Scholar
• LeeheyDJSinghAKAlaviNSinghRRole of angiotensin II in diabetic nephropathyKidney Int200058Suppl 77S93S98
   Web of Science ®Google Scholar
• TharauxPLChatziantoniouCCasellasDFouassierLArdaillouRDussauleJCVascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in ratsCirculation1999992185219110217661
   PubMed Web of Science ®Google Scholar
• SzilvassyZCsontTPaliTDroy-LefaixMTFerdinandyPNitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanineJ Vasc Res200138394611173993
   PubMed Web of Science ®Google Scholar
• ThuraisinghamRCNottCADoddSMYaqoobMMIncreased nitrotyrosine staining in kidneys from patients with diabetic nephropathyKidney Int2000571968197210792615
   PubMed Web of Science ®Google Scholar
• WalkerLMWalkerPDImamSZAliSFMayeuxPREvidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor L-N(6)-(1-Iminoethyl) lysineJ Pharmacol Exp Ther200029541742210992009
   PubMed Web of Science ®Google Scholar
• BalcellsEMengQCJohnsonWHJrOparilSDell’ItaliaLJAngiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerationsAm J Physiol19972734 Pt 2H1769H17749362242
   PubMed Web of Science ®Google Scholar
• PetrieMCPadmanabhanNMcDonaldJEHillierCConnellJMMcMurrayJJAngiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart diseaseJ Am Coll Cardiol2001371056106111263608
   PubMed Web of Science ®Google Scholar
• GriendlingKKSorescuDUshio-FukaiMNAD(P)H oxidase: role in cardiovascular biology and diseaseCirc Res20008649450110720409
   PubMed Web of Science ®Google Scholar
• HaugenENCroattAJNathKAAngiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitroKidney Int20005814415210886559
   PubMed Web of Science ®Google Scholar
• HatakeyamaHMiyamoriLFujitaTTakedaYTakedaRYamamotoHVascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cellsJ Biol Chem199428924316243207929089
   PubMed Web of Science ®Google Scholar
• SilvestreJSRobertVHeymesCMyocardial production of aldosterone and corticosterone in the rat. Physiological regulationJ Biol Chem1998273488348919478930
   PubMed Web of Science ®Google Scholar
• UllianMESchellingJRLinasSAldosterone enhances angiotensin II receptor binding and inositol phosphate responsesHypertension19922067731618554
   PubMed Web of Science ®Google Scholar
• KornelLSmoszna-KonaszewskaBAldosterone (ALDO) increases trans-membrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channelsSteroids1995601141197792795
   PubMed Web of Science ®Google Scholar
• WeberMAPurdyRECatecholamine mediated constrictor effects of aldosterone on vascular smooth muscleLife Sci198230200920177109834
   PubMed Web of Science ®Google Scholar
• IkedaUKanbeTNakayamaIKawaharaYYokoyamaMShimadaKAldosterone inhibits nitric oxide synthesis in vascular smooth muscle cells induced by interleukin-1bEur J Pharmacol199529069738575535
   PubMed Web of Science ®Google Scholar
• BrownNJNakamuraSMaLAldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivoKidney Int2000581219122710972684
   PubMed Web of Science ®Google Scholar
• EpsteinMAldosterone as a mediator of progressive renal disease: pathogenetic and clinical implicationsAm J Kidney Dis200137467768811273866
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care for patients with diabetes mellitusDiabetes Care200124Suppl 1S33S66
   PubMed Web of Science ®Google Scholar
• BakrisGLWilliamsMDworkinLPreserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working GroupAm J Kidney Dis200036364666110977801
   PubMed Web of Science ®Google Scholar
• RamsayLWilliamsBJohnstonGGuidelines for management of hypertension: report of the third working party of the British Hypertension SocietyJ Hum Hypertens199913956959210482967
   PubMed Web of Science ®Google Scholar
• FeldmanRDCampbellNLarochelleP1999Canadian recommendations for the management of hypertension. Task force for the development of the 1999 Canadian recommendations for the management of hypertensionCMAJ1999161Suppl 12S1S1710624417
   PubMed Web of Science ®Google Scholar
• ChalmersJMacMahonSManciaG1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health OrganizationClin Exp Hypertens1999215–61009106010423121
   PubMed Web of Science ®Google Scholar
• JNC-VIThe sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressureArch Intern Med199715721241324469385294
   PubMedGoogle Scholar
• LazarusJMBourgoignieJJBuckalewVMAchievement and safety of a low blood pressure goal in chronic renal disease. The modification of diet in Renal Disease Study GroupHypertension19972926416509040451
   PubMed Web of Science ®Google Scholar
• EstacioROJefersBWHiattWRBiggerstaffSLGiffordNSchrierRWThe effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertensionN Engl J Med1998338106456529486993
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 UK Prospective Diabetes Study GroupBMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study GroupLancet19983519118175517629635947
   PubMed Web of Science ®Google Scholar
• KauszATObradorGTPereiraBJAnemia management in patients with chronic renal insufficiencyAm J Kidney Dis2000366 Suppl 3S39S5111118157
   PubMed Web of Science ®Google Scholar
• LevinAThompsonCREthierJLeft ventricular mass index increase in early renal disease: impact of decline in hemoglobinAm J Kidney Dis199934112513410401026
   PubMed Web of Science ®Google Scholar
• BlockGAHulbert-ShearonTELevinNWPortFKAssociation of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national studyAm J Kidney Dis19983146076179531176
   PubMed Web of Science ®Google Scholar
• RossingPHommelESmidtUMParvingHHReduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatmentDiabetologia19943755115168056190
   PubMed Web of Science ®Google Scholar
• GansevoortRTde ZeeuwDde JongPELong-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal diseaseAm J Kidney Dis19932212022068322784
   PubMed Web of Science ®Google Scholar
• RussoDPisaniABallettaMMAdditive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathyAm J Kidney Dis19993385185610213639
   PubMed Web of Science ®Google Scholar
• CrepaldiGCartaQDeferrariGEffects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDMDiabetes Care19982111041109538979
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaAGherardiGRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaLancet1999354917635936410437863
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study InvestigatorsLancet200035525325910675071
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRfor the Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDfor the RENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• MacKinnonMShurrawSAkbariAKnollGAJaffeyJClarkHDCombination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety dataAm J Kidney Dis20064882016797382
   PubMed Web of Science ®Google Scholar
• KunzRFriedrichCWolbersMMannJFMeta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal diseaseAnn Intern Med2008148304817984482
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet200837254755318707986
   PubMed Web of Science ®Google Scholar
• BakrisGLSlataperRVicknairNSadlerRACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjectsJ Diabetes Complications199481268167383
   PubMed Web of Science ®Google Scholar
• EpsteinBJSmithSMChoksiRRecent changes in the landscape of combination RAS blockadeExpert Rev Cardiovasc Ther200971373138419900020
   PubMedGoogle Scholar
• BrunnerHRLaraghJHBaerLEssential hypertension: renin and aldosterone, heart attack and strokeN Engl J Med19722864414484257928
   PubMed Web of Science ®Google Scholar
• ParikhNIGonaPLarsonMGWangTJPlasma renin activity and risk of cardiovascular disease and mortality: the Framingham Heart StudyEur Heart J2007282644265217895253
   PubMed Web of Science ®Google Scholar
• LorigaGVidiliGRuggenentiPRenal hemodynamics and renoprotectionNephron Clin Pract2008110c213c21918974652
   PubMedGoogle Scholar
• NussbergerJGradmanAHSchmiederREPlasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertensionInt J Clin Pract200761146117590217
   PubMed Web of Science ®Google Scholar
• BrownMJAliskirenCirculation200811877378418695203
   PubMed Web of Science ®Google Scholar
• BaldonciniRDesideriGBelliniCHigh plasma renin activity is combined with elevated urinary albumin excretion in essential hypertensive patientsKidney Int1999561499150410504501
   PubMed Web of Science ®Google Scholar
• YeyatiNLAdroguéHJInappropriately high plasma renin activity accompanies chronic loss of renal functionAm J Nephrol1996164714778955757
   PubMed Web of Science ®Google Scholar
• MalmqvistKOhmanKPLindLRelationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptinJ Intern Med200225243043912528761
   PubMed Web of Science ®Google Scholar
• LicataGScaglioneRCorraoSHeredity and obesity-associated hypertension: impact of hormonal characteristics and left ventricular massJ Hypertens1995136116187594417
   PubMed Web of Science ®Google Scholar
• WeirMRBushCAndersonDRAntihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysisJASH20071426427720409858
   PubMed Web of Science ®Google Scholar
• BirkenhagerWHStaessenJADual inhibition of the renin system by aliskiren and valsartanLancet200737019519617658374
   PubMed Web of Science ®Google Scholar
• TaylorAAAndersonDRAroraVRenin system suppression with the oral direct renin inhibitor, aliskiren administered alone or in combinationJ Am Soc Nephrol200415312631333415579516
   PubMed Web of Science ®Google Scholar
• OhB-HMitchellJHerronJRChungJKhanMKeefeDLAliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertensionJ Am Coll Cardiol200749111157116317367658
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation2009119341742519139391
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet2007370958322122917658393
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLNussbergerJChiangYBedigianMPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• FramptonJECurranMPAliskiren: a review of its use in the management of hypertensionDrugs200767121767179217683174
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin Angiotensin Aldosterone Syst20078419020018205098
   PubMed Web of Science ®Google Scholar
• StrasserRHPuigJGFarsangCCroketMLiJvan IngenHA comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertensionJ Hum Hypertens20072178078717541390
   PubMed Web of Science ®Google Scholar
• DrummondWMungerMARafiqueMAntihypertensive efficacy of the oral direct renin inhibitor Aliskiren as add-on therapy in patients not responding to amlodipine monotherapyJ Clin Hypertens2007910742750
   PubMedGoogle Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens20072521722617143194
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens200720112017198906
   PubMed Web of Science ®Google Scholar
• O’BrienEBartonJNussbergerJAliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blockerHypertension20074927628417159081
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHConstanceCMComparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertensionJ Renin Angiotensin Aldosterone Syst20091015716719617271
   PubMed Web of Science ®Google Scholar
• MungerMADrummondWEssopMRAliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased edema associated with doubling the amlodipine dose [abstract]Eur Heart J200627Suppl11716267068
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAVOID Study InvestigatorsAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med20083582433244618525041
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJAliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study designNephrol Dial Transplant2009241663167119145003
   PubMed Web of Science ®Google Scholar